NCT05723562
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05723562
Title A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)
Acronym AZUR-1
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN

Facility Status City State Zip Country Details
GSK Investigational Site Los Angeles California 90027 United States Details
GSK Investigational Site Albuquerque New Mexico 87131 United States Details
GSK Investigational Site New York New York 10022 United States Details
GSK Investigational Site Pittsburgh Pennsylvania 15232 United States Details
GSK Investigational Site Nashville Tennessee 37203 United States Details
GSK Investigational Site Dallas Texas 75390 United States Details
GSK Investigational Site Richmond Virginia 23298 United States Details
GSK Investigational Site Ottawa Ontario K1H 8L6 Canada Details
GSK Investigational Site Toronto Ontario M5G 2M9 Canada Details
GSK Investigational Site Montreal Quebec H2X 0C1 Canada Details
GSK Investigational Site Sherbrooke Quebec J1H 5N4 Canada Details
GSK Investigational Site Besançon 25030 France Details
GSK Investigational Site Marseille 13273 France Details
GSK Investigational Site Paris 75012 France Details
GSK Investigational Site Pessac 33604 France Details
GSK Investigational Site Rennes 35000 France Details
GSK Investigational Site Berlin 13353 Germany Details
GSK Investigational Site Dresden 01307 Germany Details
GSK Investigational Site Düsseldorf 40225 Germany Details
GSK Investigational Site Frankfurt 60488 Germany Details
GSK Investigational Site München 81377 Germany Details
GSK Investigational Site Milan 20133 Italy Details
GSK Investigational Site Padua 35128 Italy Details
GSK Investigational Site Roma 00168 Italy Details
GSK Investigational Site Chiba 277-8577 Japan Details
GSK Investigational Site Kanagawa 232-0024 Japan Details
GSK Investigational Site Osaka 540-0006 Japan Details
GSK Investigational Site Osaka 565-0871 Japan Details
GSK Investigational Site Utrecht 3584 CX Netherlands Details
GSK Investigational Site Seoul 05505 South Korea Details
GSK Investigational Site Seoul 06591 South Korea Details
GSK Investigational Site Seoul 120-752 South Korea Details
GSK Investigational Site Seoul 135-710 South Korea Details
GSK Investigational Site Barcelona 08035 Spain Details
GSK Investigational Site Granada 18014 Spain Details
GSK Investigational Site Madrid 28007 Spain Details
GSK Investigational Site Madrid 28041 Spain Details
GSK Investigational Site Santander 39008 Spain Details
GSK Investigational Site Valencia 46010 Spain Details
GSK Investigational Site Leeds West Yorkshire LS9 7TF United Kingdom Details
GSK Investigational Site London EC1A 7BE United Kingdom Details
GSK Investigational Site Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field